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Objective: No consistent data are present in literature about the effectiveness of Levothyroxine (L-T4) liquid formulation
in patients without malabsorption after thyroidectomy. The aim of this study is to compare the effectiveness of L-T4 liquid for-
mulation, with L-T4 tablets, in thyroid cancer patients after thyroidectomy (without malabsorption or drug interference).
Methods: One hundred ﬁve patients were recruited; 52 patients were treated with liquid L-T4 formulation, while 53 with
L-T4 tablets, at the same dosage (1.5 mcg/kg/day). Patients started to assume the drug the day after surgery, 30 min before
breakfast. In both groups circulating levels of thyrotropic hormone (TSH), free thyroxine (FT4), and free triiodothyronine
(FT3) were dosed at week 6 (ﬁrst control), and then at week 12 (second control).
Results: We obtained signiﬁcantly lower TSH values in the liquid L-T4 group patients, compared to the tablet L-T4 group,
at the ﬁrst control (P < .05), and at the second control (P < .01), while FT4 and FT3 levels were not signiﬁcantly different.
Hypothyroid range (TSH > 3.6 mcU/mL) was signiﬁcantly more prevalent in the patients treated with L-T4 tablet.
Conclusions: A better control of TSH was observed in thyroidectomized patients (without malabsorption, gastric disor-
ders, or drug interference) with liquid L-T4 regimen.
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INTRODUCTION
Hypothyroidism is a widespread clinical entity espe-
cially among middle-aged and elderly people, and it is
well treated with Levothyroxine (L-T4).1,2
After an adequate low pH-dependent melting process
in the gastric environment, the L-T4 tablets, when given
orally, are mainly (70%) absorbed by duodenum, jejunum,
and ileum.3,4
Several gastrointestinal diseases and swallowed sub-
stances can interfere with the correct L-T4 absorption,5
as for example: lactose intolerance, intestinal parasitic
diseases, Helicobacter pylori–associated gastritis, autoim-
mune gastritis, or presence of parietal cells autoanti-
bodies, celiac disease, bariatric surgery, and coffee.6–10
Beyond the classical tablet form, new formulations of
thyroxine, such as soft gel capsule and oral solution, can
now be prescribed.
Several studies have demonstrated that we could
reach, in both adults and children, a higher percent of L-
T4 absorption when it is given in liquid solution rather
than in solid tablet.11
Physicians usually attempt to achieve the desired
thyroid-stimulating hormone (TSH) range by increasing
the L-T4 daily prescription, even in those patients with
concomitant factors (drugs, bariatric surgery or coffee
consumption) that can alter the L-T4 tablets absorption.
In vivo studies have proved how L-T4 oral solution can
overcome this malabsorption issue. This new formulation
shows to be also proper in patients unlikely to change
their routine or with solid dysphagia.12–14
The liquid formulation has been shown to overcome:
1) the food and beverages interference with L-T4 tablets
absorption, caused by food at breakfast15; 2) malabsorption
induced by the increased gastric pH, resulting from atro-
phic gastritis, or due to proton-pump inhibitors16; 3) mal-
absorption after bariatric surgery17; and 4) malabsorption
induced by lactose intolerance, or drug interference.18–20
Finally, liquid L-T4 is more active than tablets in
the control of TSH in hypothyroid patients without mal-
absorption, drug interference, or gastric disorders, lead-
ing to hypothesize a higher absorption of liquid L-T4 also
in these patients.21,22
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However, until now, to the best of our knowledge, no
consistent data are present in literature about the effec-
tiveness of L-T4 liquid formulation in patients immedi-
ately after thyroidectomy for thyroid cancer.
The aim of this study is to compare the effectiveness
of L-T4 liquid formulation, with L-T4 tablets, in patients
operated for thyroid cancer, when absorption impairment
or drug interference have been ruled out.
PATIENTS AND METHODS
This is an observational, prospective study, con-
ducted in patients with L-T4 regimen, as substitutive
therapy after total thyroidectmy for thyroid cancer, from
January 2015 to December 2016.
Inclusion criteria were: 1) patients affected by differ-
entiated papillary or follicular thyroid cancer operated for
total thyroidectomy (the decision-making process for the
surgery was made following the Revised American Thy-
roid Association management guidelines for patients with
thyroid nodules and differentiated thyroid cancer [DTC]23
[Thyr3- Thyr4- Thyr5]); 2) age of 18 to 75 years; 3) TSH
levels at last control (within 1 month before operation) of
0.5–4 mcU/mL, without L-T4 therapy; and 4) patients
consent to participate in the study.
Exclusion criteria were: 1) serious psychiatric disor-
ders; 2) inability to understand the aim of the study and
to adhere it; 3) inability to give an acceptable consent; 4)
abuse of alchool or drugs; 5) patients in whom histologi-
cal examination did not conﬁrm the suspicious of thyroid
cancer; 6) allergy or intolerance to the considered drugs;
7) previous neoplasia during therapy in the last 5 years;
8) hepatitis C or B; 9) altered liver function tests; 10)
renal impairment (Modiﬁcation of Diet in Renal Disease
[MDRD] < 30 ml/min/1.73 mq); 11) history of atrial
ﬁbrillation or other tachyarrhythmias, coronary artery
disease (CAD); 12) severe anemia (haemoglobin [Hb] <
10 gr/dL]); 13) previous or concurrent atrophic gastritis,
H. Pylori-associated gastritis, celiac disease, intestinal
malabsorption, lactose intolerance; 14) earlier bariatric
or intestinal or gastric surgery; 15) pregnancy; 16) con-
current therapy with proton pump inhibitors, or
antiacids, beta-blockers, raloxifen, lithium, cholestyr-
amine, interferons, amiodaron, orlistat; or 17) urinary
iodine > 250 mg/dL.
Other gastrointestinal diseases were assessed in
patients to prevent bias in the evaluation of T4 malab-
sorption: 1) excluding anemia deriving from VitB12 or
iron deﬁciency; well-established uninvestigated dyspep-
sia, associated with fullness, bloating, or burning; or a
combination of these conditions; or diarrhea; and 2) eval-
uating the presence of H. pylori antigen in the stool.4
Patients with positive results were excluded from the
study.
The study involved 105 patients, 53 of whom treated
with L-T4 in tablets, and 52 with liquid L-T4 (Tirosint
vial, IBSA Farmaceutici Italia, Lodi, Italy), at the same
dosage (1.5 mcg/kg/day). The 105 patients were evaluated
both after 6 weeks, and 12 weeks from thyroidectomy
(87 females, 18 males; mean age 48 ± 15.7 years; 96 with
papillary thyroid cancer, and 9 with follicular thyroid
cancer); without any signiﬁcant difference in the two
groups (Table I). Among the enrolled patients treated
with liquid or tablet L-T4, none were lost at follow-up.
Patients gave consent to take thyroxine on fasting,
avoiding meals or drinks apart from water for at least
30 minutes (before breakfast) after L-T4 therapy in tab-
lets or in the liquid formulation. Circulating levels of
TSH, free thyroxine (FT4) and free triiodothyronine (FT3)
were dosed after 6 weeks (ﬁrst control), and 12 weeks
(second control) from thyroidectomy. The local ethical
committee accepted the study.
Circulating levels of FT4 (normal range, 0.7–1.7
ng/dL), FT3 (normal range, 2.7–4.7 pg/mL), and TSH (nor-
mal range, 0.4–4 mcU/mL) were assessed in all blood sam-
ples by electrochemiluminescence immunoassay (Roche
Corporation, Indianapolis, IN, U.S.A.). The concentration
of each hormone was calculated as a mean of two blood
samples collected before assuming the L-T4 daily dose.
Data Analysis
Values are given as mean ± SD for normally distrib-
uted variables, or as median and (interquartile range;
IQR1–IQR3). For normally distributed variables (age and
body mass index (BMI)], one-way ANOVA was used to
compare group values. Bonferroni-Dunn test or Fisher
PLSD were utilized for post-hoc comparisons on normally
distributed variables. For not normally distributed vari-
ables (as L-T4 dose, TSH, etc.), Kruskal Wallis test (>3
groups) or Mann Whitney test (2 groups) were used. χ2
test was applied to compare proportions.
RESULTS
The ﬁrst evaluation was made after 6 weeks from
the initial thyroidectomy (41 ± 5 days), while the second
evaluation was made after 12 weeks (85 ± 7 days). Body
weight was not signiﬁcantly changed (BMI, base
24.5 ± 2.8 kg/m2, ﬁrst control 24.4 ± 2.7 kg/m2, second
control 24.5 ± 2.5 kg/m2); without any signiﬁcant differ-
ence in the two groups.
TSH levels were signiﬁcantly lower in patients treated
with liquid L-T4, compared to those treated with the tablet
formulation, at the ﬁrst control (P < .05), and at the second
control (P < .01) (Fig. 1). FT4 and FT3 levels were not sig-
niﬁcantly changed (data not shown). No differences in TSH
were reported in patients aged ≤ 50, or > 50 years.
TABLE I.
Demographic Data Patients Treated With Liquid L-T4 or Tablet
L-T4.
Liquid-LT4 Tablet-LT4 P value
Dosage 1.5 mcg/kg/day 1.5 mcg/kg/day
Number 52 53
Female/male 44/8 43/10 .635
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The prevalence of patients in the hypothyroid range
(TSH > 3.6 mcU/mL) was signiﬁcantly higher in the L-T4
tablet group (7, 13.5%), with respect to the liquid L-T4
group (1, 1.8%) (P = .029).
DISCUSSION
These data demonstrate for the ﬁrst time the effec-
tiveness of liquid L-T4 over the solid form to achieve the
desired TSH levels in patient who had undergone total
thyroidectomy because of thyroid cancer.
Considering that the drug dosage was the same
between both groups, we suppose that the different TSH
level could be associated with a higher absorption of L-T4
in the liquid formulation; the underlying mechanisms is
not well-known yet.11
The low pH value of the gastric environment is man-
datory for the correct melting of L-T4 tablets and its solu-
bility could be impaired by several factors.19,20,24,25
Therefore, we have recruited patients without malabsorp-
tion or gastric diseases, nor drug interference.
Previous analysis established that liquid L-T4 does
not require acid dissolution in the stomach but it can
directly pass through gut mucosa showing quicker absorp-
tion time (area under the curve from 0 to 2 h wider than
50%; time to maximum concentration faster by a mean of
30 min), and overall better pharmacokinetics proﬁle.26–29
The L-T4 oral solution contains also alcohol, which
allows the drug to be delivered directly to the highly vascu-
larized buccal mucosa, and reaching straight the systemic
bloodstream bypassing the gastrointestinal tract,30 even if
we need more studies to elucidate this process.
Other studies have evaluated liquid L-T4 in patients
with thyroid cancer.
A ﬁrst study evaluated the tolerability and efﬁcacy
of a new formulation of liquid L-T4 versus the previous
tablet formulation in 59 patients with cured DTC. Hor-
monal and clinical evaluations were performed before
and 70 days after patients were switched from tablet to
liquid L-T4 formulation, without changes in daily dose.
No change in TSH, thyroid hormones, or thyroglobulin
(Tg) was noted during the study.12
A second study evaluated the TSH variability of
patients affected by DTC treated with liquid L-T4 formu-
lation or in tablet form. Patients were randomized (1:1) to
receive treatment of hypothyroidism with liquid L-T4
(51 patients) or tablet form (51 patients). The ﬁrst check-
up evaluation was made from 8 to 12 months after 131I
remnant ablation. TSH values were established again
after further 12 months. A signiﬁcant increase in TSH
levels (median) was observed in patients taking tablets,
as compared to those taking liquid formulation. These
data suggest that the use of L-T4 liquid formulation, as
compared to that of tablets, resulted in a signiﬁcantly
higher number of DTC patients maintaining TSH values
in range for the American Thyroid Association (ATA) risk
score, reducing TSH variability over the time 31.
However, to the best of our knowledge, this is the
ﬁrst study that evaluated liquid L-T4 in patients with
thyroid cancer immediately after total thyroidectomy.
Our data show that the use of L-T4 liquid formulation, as
compared to that of tablets, resulted in a signiﬁcantly
higher number of DTC patients maintaining TSH values
in the normal range after thyroidectomy.
The importance of TSH suppression in general and
the degree of suppression in particular in preventing
recurrence and adverse clinical events have been taken
into account in the recently updated guidelines from the
ATA which indicate that in many patients, the serum TSH
should be maintained between 0.1 and 0.5 mcU/mL, taking
into account the initial ATA risk classiﬁcation, Tg level, its
trend over the time, and the risk of TSH suppression.32
However, the potential beneﬁts of reaching the therapeutic
goal must always be balanced against possible adverse
effects of subclinical thyrotoxicosis including exacerbation
of angina in patients with ischemic heart disease,
increased risk for atrial ﬁbrillation in older patients, and
increased risk of osteoporosis in postmenopausal women.
In conclusion, on the whole, our data support a bet-
ter control of TSH values in thyroidectomized thyroid
cancer patients (without malabsorption, gastric disorders,
or drug interference) in liquid L-T4 regimen, with respect
to L-T4 in tablets.
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